Literature DB >> 32567723

Reduced survival in patients who return to dialysis after kidney allograft failure.

Liliana Bisigniano1, Gustavo Laham2, Maria Cora Giordani3, Viviana Tagliafichi1, Daniela Hansen Krogh1, Alberto Maceira1, Guillermo Javier Rosa-Diez3.   

Abstract

BACKGROUND: The outcome of patients who return to dialysis after Kidney allograft failure (KAF) remains unclear. Our aim was to compare the outcome of KAF patients vs two different types of transplant naive incident dialysis (TNID) patients, those on the waiting list (WL) and those with a kidney transplant contraindication (KTC).
METHODS: We performed an observational study using data from the Argentinian Dialysis Registry between 2005 and 2016. We compare mortality between KAF, WL, and KTC.
RESULTS: We included 75 722 patients of which 2734 were KAF. Survival between the three cohorts (KAF vs WL (n = 14 630) vs KTC (n = 58 358) revealed a significant difference (log-rank test: P < .0001) indicating worse survival for KTC patients and best survival for WL. We found that KAF patients had as poor outcome as KTC patients after multivariate adjustment. Cox regression showed that age >65 years: HR: 1.845 (1.79-1.89) P < .0001, transient catheter: HR: 1.303 (1.26-1.34) P < .0001, diabetic: HR: 1.273 (1.22-1.31) P < .0001, hepatitis C: HR: 1.156 (1.09-1.22) P < .0001, and albumin: HR: 1.247 (1.21-1.28) P < .0001 were associated with mortality.
CONCLUSION: Patients who return to dialysis after KAF have higher mortality than WL patients and similar to KTC patients.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  dialysis; kidney allograf failure; patients survival

Mesh:

Year:  2020        PMID: 32567723     DOI: 10.1111/ctr.14014

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  1 in total

1.  Returning to dialysis after kidney allograft failure: the experience of the Italian Registry of Paediatric Chronic Dialysis.

Authors:  Edoardo La Porta; Ester Conversano; Enrico Vidal; Enrico Verrina; Daniela Zugna; Roberta Camilla; Raffaella Labbadia; Fabio Paglialonga; Mattia Parolin
Journal:  Pediatr Nephrol       Date:  2021-06-14       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.